{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:17:16Z","timestamp":1790381836003,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,9,5]],"date-time":"2016-09-05T00:00:00Z","timestamp":1473033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,9,5]],"date-time":"2016-09-05T00:00:00Z","timestamp":1473033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1038\/bmt.2016.222","type":"journal-article","created":{"date-parts":[[2016,9,5]],"date-time":"2016-09-05T13:47:26Z","timestamp":1473083246000},"page":"1565-1568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":180,"title":["Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis"],"prefix":"10.1038","volume":"51","author":[{"given":"O","family":"Landgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Boulad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,5]]},"reference":[{"key":"BFbmt2016222_CR1","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/leu.2014.23","volume":"28","author":"SY Kristinsson","year":"2014","unstructured":"Kristinsson SY, Anderson WF, Landgren O . Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia 2014; 28: 1346\u20131348.","journal-title":"Leukemia"},{"key":"BFbmt2016222_CR2","unstructured":"US Food and Drug Administration. Hematology\/Oncology (Cancer) Approvals & Safety Notifications. 2016 Available at: http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm279174.htm."},{"key":"BFbmt2016222_CR3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","volume":"12","author":"S Mailankody","year":"2015","unstructured":"Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol 2015; 12: 286\u2013295.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFbmt2016222_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/cyto.b.21268","volume":"90","author":"NJ Gormley","year":"2016","unstructured":"Gormley NJ, Turley DM, Dickey JS, Farrell AT, Reaman GH, Stafford E et al. Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma. Cytometry B Clin Cytom 2016; 90: 73\u201380.","journal-title":"Cytometry B Clin Cytom"},{"key":"BFbmt2016222_CR5","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","volume":"1","author":"N Korde","year":"2015","unstructured":"Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol 2015; 1: 746\u2013754.","journal-title":"JAMA Oncol"},{"key":"BFbmt2016222_CR6","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1182\/blood-2014-05-573733","volume":"124","author":"MV Mateos","year":"2014","unstructured":"Mateos MV, Oriol A, Martinez-Lopez J, Teruel AI, Lopez de la Guia A, Lopez J et al. GEM2005 trial update comparing VMP\/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood 2014; 124: 1887\u20131893.","journal-title":"Blood"},{"key":"BFbmt2016222_CR7","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","volume":"112","author":"B Paiva","year":"2008","unstructured":"Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008; 112: 4017\u20134023.","journal-title":"Blood"},{"key":"BFbmt2016222_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bjh.12139","volume":"160","author":"R Silvennoinen","year":"2013","unstructured":"Silvennoinen R, Kairisto V, Pelliniemi TT, Putkonen M, Anttila P, Saily M et al. Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients. Br J haematol 2013; 160: 561\u2013564.","journal-title":"Br J haematol"},{"key":"BFbmt2016222_CR9","unstructured":"Team RC R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria, 2015."},{"key":"BFbmt2016222_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W . Conducting meta-analyses in R with the metafor package. J Stat Softw 2010; 36: 1\u201348.","journal-title":"J Stat Softw"},{"key":"BFbmt2016222_CR11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood.V96.1.355","volume":"96","author":"M Cavo","year":"2000","unstructured":"Cavo M, Terragna C, Martinelli G, Ronconi S, Zamagni E, Tosi P et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 2000; 96: 355\u2013357.","journal-title":"Blood"},{"key":"BFbmt2016222_CR12","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","volume":"102","author":"P Corradini","year":"2003","unstructured":"Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003; 102: 1927\u20131929.","journal-title":"Blood"},{"key":"BFbmt2016222_CR13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.leukres.2005.01.017","volume":"29","author":"S Galimberti","year":"2005","unstructured":"Galimberti S, Benedetti E, Morabito F, Papineschi F, Callea V, Fazzi R et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res 2005; 29: 961\u2013966.","journal-title":"Leuk Res"},{"key":"BFbmt2016222_CR14","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.exphem.2006.01.011","volume":"34","author":"N Kroger","year":"2006","unstructured":"Kroger N, Zagrivnaja M, Schwartz S, Badbaran A, Zabelina T, Lioznov M et al. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma. Exp Hematol 2006; 34: 688\u2013694.","journal-title":"Exp Hematol"},{"key":"BFbmt2016222_CR15","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","volume":"28","author":"M Ladetto","year":"2010","unstructured":"Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28: 2077\u20132084.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016222_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JCO.2011.39.5137","volume":"31","author":"H Ludwig","year":"2013","unstructured":"Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O et al. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol 2013; 31: 247\u2013255.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016222_CR17","first-page":"397","volume":"84","author":"G Martinelli","year":"1999","unstructured":"Martinelli G, Terragna C, Lemoli RM, Cavo M, Benni M, Motta MR et al. Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells. Haematologica 1999; 84: 397\u2013404.","journal-title":"Haematologica"},{"key":"BFbmt2016222_CR18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/sj.bmt.1702379","volume":"25","author":"R Powles","year":"2000","unstructured":"Powles R, Sirohi B, Kulkarni S, Bhagwati N, Saso R, Raje N et al. Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - a phase I\/II feasibility and tolerance study of 17 patients. Bone Marrow Transplant 2000; 25: 949\u2013956.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016222_CR19","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","volume":"31","author":"AC Rawstron","year":"2013","unstructured":"Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013; 31: 2540\u20132547.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016222_CR20","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","volume":"125","author":"AC Rawstron","year":"2015","unstructured":"Rawstron AC, Gregory WM, de Tute RM, Davies FE, Bell SE, Drayson MT et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood 2015; 125: 1932\u20131935.","journal-title":"Blood"},{"key":"BFbmt2016222_CR21","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"M Roussel","year":"2014","unstructured":"Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol 2014; 32: 2712\u20132717.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016222_CR22","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","volume":"123","author":"J Martinez-Lopez","year":"2014","unstructured":"Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonzalez M, Barrio S, Ayala R et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014; 123: 3073\u20133079.","journal-title":"Blood"},{"key":"BFbmt2016222_CR23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","volume":"119","author":"B Paiva","year":"2012","unstructured":"Paiva B, Gutierrez NC, Rosinol L, Vidriales MB, Montalban MA, Martinez-Lopez J et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012; 119: 687\u2013691.","journal-title":"Blood"},{"key":"BFbmt2016222_CR24","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1200\/JCO.2010.33.1967","volume":"29","author":"B Paiva","year":"2011","unstructured":"Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montalban MA, Fernandez-Redondo E et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011; 29: 1627\u20131633.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016222_CR25","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1038\/bcj.2014.69","volume":"4","author":"R Silvennoinen","year":"2014","unstructured":"Silvennoinen R, Lundan T, Kairisto V, Pelliniemi TT, Putkonen M, Anttila P et al. Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma. Blood cancer J 2014; 4: e250.","journal-title":"Blood cancer J"},{"key":"BFbmt2016222_CR26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/leu.2014.219","volume":"29","author":"S Ferrero","year":"2015","unstructured":"Ferrero S, Ladetto M, Drandi D, Cavallo F, Genuardi E, Urbano M et al. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. Leukemia 2015; 29: 689\u2013695.","journal-title":"Leukemia"},{"key":"BFbmt2016222_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.2014.56.4351","volume":"33","author":"IE Ahn","year":"2015","unstructured":"Ahn IE, Mailankody S, Korde N, Landgren O . Dilemmas in treating smoldering multiple myeloma. J Clin Oncol 2015; 33: 115\u2013123.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016222_CR28","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/ajh.23831","volume":"89","author":"O Landgren","year":"2014","unstructured":"Landgren O, Gormley N, Turley D, Owen RG, Rawstron A, Paiva B et al. Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium. Am J Hematol 2014; 89: 1159\u20131160.","journal-title":"Am J Hematol"},{"key":"BFbmt2016222_CR29","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","volume":"120","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S et al. A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012; 120: 1801\u20131809.","journal-title":"Blood"},{"key":"BFbmt2016222_CR30","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17: e328\u2013e346.","journal-title":"Lancet Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2016222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016222","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:28:13Z","timestamp":1648063693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2016222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,5]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["BFbmt2016222"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2016.222","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,5]]},"assertion":[{"value":"25 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}